Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis.

ABSTRACT:

Background

Subcutaneous peginterferon beta-1a every 2 weeks significantly affects clinical outcomes in patients with relapsing-remitting multiple sclerosis (RRMS).

Objectives

To explore relationships between relapses and worsening of disability in patients with RRMS, and assess the treatment effect of peginterferon beta-1a on relapse recovery.

Methods

Post-hoc analysis of the 2-year, randomized, double-blind, parallel-group, Phase 3 ADVANCE study. The severity of relapses, proportion of patients with relapses associated with residual disability (onset of 24-week confirmed disability progression (CDP) within 90 days following a relapse), and persistence of changes in Functional Systems Scores, were compared between treatment groups.

Results

Subcutaneous peginter

SUBMITTER: Scott TF 

PROVIDER: S-EPMC5433498 | biostudies-literature | 2016 Jan-Dec

REPOSITORIES: biostudies-literature